TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Transjugular Intrahepatic Portosystemic Shunts on Liver Stiffness

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic portal hypertension secondary to cirrhosis undergoing elective outpatient TIPS~* Age \>18, Age \<80~* Capable of giving informed consent~Exclusion Criteria:~* Coagulopathy defined as international normalized ration (INR) \>2 which cannot be corrected with fresh frozen plasma~* Platelet count \<50,000/microliter, which cannot be corrected with platelet transfusion~* BMI \>35 and/or cirrhosis due to non-alcoholic steatohepatitis (due to inaccurate elastography measurements in patients with fatty liver)~* Urgent or emergent TIPS for bleeding~* Portal vein thrombosis with in the main, 1st, or 2nd order branches of the portal vein~* Hepatic vein thrombosis (ie no Budd Chiari syndrome)~* Excessive alcohol use defined as more than 2 oz in 24 hours on any individual day within the last 30 days~* Inability to provide informed consent~* Pregnant or nursing women~* Enrollment in concurrent therapeutic trial for symptomatic portal hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Open Label (Type: OTHER): All enrolled participants will undergo hepatic ultrasound with acoustic radiation force impulse (ARFI) before and 30 days after creation of TIPS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Serological Test s for the Virus Chicken Pox Virus (VZV) and Correlation With the Patient's Memory of the Infection or Vaccination

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women aged over 18~* Affiliated to a social protection scheme or women benefiting from such a regime~* Women who gived a writing consent~Exclusion Criteria:~* Women with a maternal disease: autoimmune disease (systemic lupus erythematosus, antiphospholipid syndrome, insulin dependent diabetes, autoimmune thyroiditis ..), it takes an immunosuppressive treatment or not.~* HIV-positive women~* Garfted women whatever organ

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pregnant women (Type: EXPERIMENTAL): Pregnant women

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Predicting Migraine Attacks Based on Environmental and Behavioral Changes as Detected From the Smartphone

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Individuals who suffer from episodic migraine with 4-14 days of migraine per month (ICHD-3 patients).~* Individuals who possess a smartphone - Android version 5.0 and above or iOS version 10.0 and above.~Exclusion Criteria:~* Individuals who are unable to sign the consent form.~* Pregnant women.~* Individuals suffering from headaches that do not meet the IHS migraine criteria or don't have moderate to severe chronic pain of VAS chronic grade 4 and above.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Estrogen Diastolic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 28 healthy recently postmenopausal women with last menstrual bleeding 12 months at study entry. Women with last menstrual bleeding within 12 months at study entry are those who are peri-menopausal and for whom the drug is FDA approved.~Exclusion Criteria:~* History of hysterectomy, oophorectomy or both~* History of heart disease including cardiac transplantation, heart failure, bypass surgery or percutaneous intervention, and valve disease defined as moderate or severe valve regurgitation or stenosis~* History of bone disease including non-traumatic vertebral fractures on radiography~* Uncontrolled chronic disease (including uncontrolled diabetes defined as a hemoglobin A1C \>8, uncontrolled hypertension defined as a systolic blood pressure \>160 mmHg, awaiting organ transplant)~* Previous or current cancer, excluding basal cell carcinoma~* Previous or current thromboembolic disease~* Previous intolerance of Hormone replacement therapy (HRT) or Oral contraception (OC)~* Current or previous use of HRT within the past 3 months~* Current or recent (\<12 months) substance abuse, including tobacco use~* No drug interactions with HRT~* No racial or ethnic groups will be excluded

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Hormone replacement therapy (Type: ACTIVE_COMPARATOR): Estradiol/norethindrone acetate 1mg/0.5 mg by mouth oral daily for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Inert ingredients by mouth oral daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Low-risk Fever and Neutropenia in Children With Cancer: Safety and Efficacy of Oral Antibiotics in an Outpatient Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chemotherapy because of malignancy~* Severe neutropenia (absolute neutrophil count ≤ 0.5x10E9/L)~* Fever (axillary temperature ≥ 38.5°C once or ≥ 38.0°C during ≥ 2 hours)~* Able to swallow oral medication~* Written informed consent from patients and/or parents~Exclusion Criteria:~* Status post myeloablative chemotherapy~* Diagnosis: acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or B-cell Non-Hodgkin lymphoma~* Bone marrow involvement by malignancy ≥ 25%~* Any comorbidity requiring hospitalization: \[1\] mean arterial blood pressure \< 50 mmHg (up to 10 years) / \< 60 mmHg (older than 10 years); \[2\] oxygen saturation \< 94% at room air; \[3\] radiologically defined pneumonia; \[4\] focal bacterial infection; \[5\] blood cultures taken at presentation reported positive at reassessment; \[6\] need for inpatient treatment or observation due to any other reason, as judged by the physician in charge~* Ever shaking chills~* Ever axillary temperature ≥ 39.5°C~* Antibacterial treatment before presentation with fever and neutropenia (except for prevention against Pneumocystis jiroveci \[formerly P. carinii\] pneumonia)~* Modification or de novo institution of a prophylaxis against P. jiroveci pneumonia~* Modification or de novo institution of a therapy with G-CSF or GM-CSF.~* Allergy to ciprofloxacin and/or amoxicillin~* Serum creatinine level above the upper limit of normal range

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Standard (Type: ACTIVE_COMPARATOR): Continued inpatient i.v. antibiotics
- Experimental (Type: EXPERIMENTAL): Switch to outpatient p.o. antibiotics

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Signed informed consent, release of medical information, and Health Insurance Portability and Accountability Act (HIPAA) documents~* Male, postmenopausal female, or female who may become pregnant but is using adequate contraceptive precautions (defined as use of oral contraceptive, intrauterine devices, surgical contraception, or a combination of a condom and a spermicide), with negative pregnancy test~* Admitted to the clinical center at the time of study entry~* Listed with United Network for Organ Sharing (UNOS) for cardiac transplantation~* Clinical indication and accepted candidate for implantation of an FDA approved LVAD as a bridge to transplantation~* Hemoglobin between 9.0 gm/dl and 16.1 gm/dl within 24 hours prior to study entry~* Platelet count between 100,000/ul and 450,000/ul within 24 hours prior to study entry~* White blood cell count between 2,500/ul and upper limit of normal within 24 hours prior to study entry~Exclusion Criteria~* Cardiothoracic surgery within 30 days prior to study entry~* Myocardial infarction within 6 months prior to study entry~* Prior cardiac transplantation, left ventricular (LV) reduction surgery, or cardiomyoplasty~* Acute reversible cause of heart failure (e.g., myocarditis, profound hypothyroidism)~* Anticipated requirement for biventricular mechanical support~* Stroke within 30 days prior to study entry~* Received investigational intervention within 30 days of study entry~* Pregnant or breastfeeding at time of study entry~* HIV positive within 30 days prior to study entry~* Active systemic infection within 48 hours prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Intramyocardial injection of bone marrow mononuclear cells + LVAD
- Group 2 (Type: EXPERIMENTAL): Intramyocardial injection of CD34+ selected bone marrow mononuclear cells + LVAD
- Group 3 (Type: OTHER): LVAD alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ASpirin as a Treatment for ARDS (STAR): a Phase 2 Randomised Control Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients receiving invasive mechanical ventilation.~2. ARDS as defined by the Berlin definition.~   * Onset within 1 week of identified insult.~  * Within the same 24 hours~     * Hypoxic respiratory failure (PaO2/ FiO2 ratio ≤ 40kPa on PEEP ≥ 5 cmH20),~    * Bilateral infiltrates on chest X-ray consistent with pulmonary oedema not explained by another pulmonary pathology,~    * No evidence of heart failure or volume overload~Exclusion Criteria:~1. More than 72 hours from the onset of ARDS.~2. Age \< 16 years.~3. Patient is known to be pregnant.~4. Participation in a clinical trial of an investigational medicinal product within 30 days.~5. Current treatment with aspirin or within the past 4 weeks.~6. Platelet count \< 50 x 109/l.~7. Haemophilia or other haemorrhagic disorder or concurrent therapeutic anticoagulant therapy.~8. History of aspirin sensitive asthma or nasal polyps associated with asthma.~9. Active or history of recurrent peptic ulcer and/ or gastric/ intestinal haemorrhage or other kinds of bleeding such as cerebrovascular haemorrhage.~10. Traumatic brain injury.~11. Active gout.~12. Currently receiving methotrexate.~13. Severe chronic liver disease with Child-Pugh score \> 12.~14. Known hypersensitivity or previous adverse reaction to salicylic acid compounds or prostaglandin synthetase inhibitors.~15. Physician decision that aspirin is required for proven indication.~16. Contraindication to enteral drug administration, e.g. patients with mechanical bowel obstruction.~17. Treatment withdrawal imminent within 24 hours.~18. Consent declined.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aspirin 75mg (Type: EXPERIMENTAL): Aspirin 75mg enterally once daily for a maximum of 14 days
- Placebo (Type: PLACEBO_COMPARATOR): Lactose powder placebo enterally once daily for a maximum of 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of VistaO2 FLUX Device in Screening of Sleep Apnea/Hypopnea Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* sleep apnea hypopnea syndrome suspicion~* written consent~Exclusion Criteria:~* pacemaker~* diabetes~* atrial fibrillation~* electrode allergy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- VistaO2 FLUX device (Type: EXPERIMENTAL): This device combines the transcutaneous oxyhemoglobin saturation (allowing to compute the oxyhemoglobin desaturation index), the slow variations in heart rate, the nasal flow and an index of nocturnal respiratory events calculated by analyzing the movements of the chest performed by chest impedance variations.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Blood Biomarkers of Injury and Outcome in Traumatic Brain Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe brain injury (iGCS 12-4 or motor response 2-5 if intubated).~* Age \>18 years (or developmental stage Tanner 5 in patients where age is not known)~* Blunt, traumatic, closed head injury (altered mental status due to brain injury)~* Able to initiate study drug infusion within 4 hours from time of injury -~Exclusion Criteria:~* Non-survivable injury as determined by treating~* Bilateral dilated unresponsive pupils~* Spinal cord injury with neurological deficits, pre-injury paralysis (quad/paraplegic)~* Inability to perform activities of daily living (ADL) without assistance~* Cardiopulmonary arrest~* Status epilepticus on arrival or concern for post ictal state~* systolic blood pressure \< 90 for two consecutive readings at least 5 minutes apart any time prior to randomization~* O2 Sat \< 90 for at least 5 consecutive minutes any time prior to randomization~* Prisoner or ward of state~* Known active breast or reproductive organ cancers (via medical records or family interview)~* Known allergy to progesterone or Intralipid components (egg yolk) (via medical records or family interview)~* Known history of blood clotting disorder (Protein S or C deficiency, etc.) or history of pulmonary embolism (via medical records or family interview) or active/ongoing thromboembolic event (myocardial infarction, ischemic stroke, pulmonary embolism, deep vein thrombosis).~* Blood or serum ethanol (EtOH) ≥ 250 mg %~* Positive qualitative urine or serum pregnancy test~* Concern for inability to follow up at 6 months (residence in foreign country, homeless with limited contacts,~* undocumented immigrants, or high likelihood of becoming incarcerated during study period, etc.)~* Patient in Opt Out registry or wearing Opt Out bracelet -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- On progesterone treatment (Type: None): The group assigned to progesterone treatment.
- group assigned to placebo (Type: None): The group that will not be receiving progesterone treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Non Small Cell Lung Cancer (NSCLC) patients who were previously untreated receiving anti-PD1 or anti-PD-L1 therapies, either single agent or in combination with chemotherapy.~* NSCLC patients who were treated with one previous line of therapy (not containing IO) and now receiving anti-PD1 or anti-PD-L1 therapies, either single agent or in combination with chemotherapy.~Exclusion Criteria:~* Patients not capable of making medical decisions~* Any patients who do not meet the inclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of the Effectivity of Total-face Mask for Noninvasive Ventilation During Acute Respiratory Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Acute Hypoxemia:PaO2/FiO2 lower than 200 mmHg~* Respiratory rate greater than 30 breaths/min~Exclusion Criteria:~* cardiogenic lung edema~* COPD exacerbation~* Low level of consciousness (GCS \< 13)~* Hemodynamic instability~* Facial damage~* Do-not-intubate orders~* Lack of informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Reminders Through Association & Prescription Adherence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must be capable of sending and receiving text and picture messages on their phone.~Exclusion Criteria:~* Participants will only be excluded if they participated in the pilot study in which the investigators enrolled 150 participants. These participants will be excluded when they attempt to text the investigators to enroll.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Reminders Through Association Arm (Type: EXPERIMENTAL): participants will be prompted to think of a reminder cue that will help them remember to pick up the prescription.
- Active Control Arm (Type: ACTIVE_COMPARATOR): Participants will be asked to think about where they will store their prescription.
- Baseline Control Arm (Type: ACTIVE_COMPARATOR): Participants are thanked for enrolling in the reminder program.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable Alzheimer's Disease~* Has completed participation in solanezumab Study LZAM or Study LZAN through 80 weeks~* Must continue to have a reliable caregiver who is in frequent contact with the patient for the entire study~* Must have good vein access to administer infusions~* Agrees not to participate in studies of any other investigational compounds for the duration of their participation in Study LZAO~Exclusion Criteria:~* Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device or off-label use of a drug or device (other than the study drug/device used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study~* Meets LZAM or LZAN discontinuation criteria at the end of treatment in LZAM or LZAN study

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Solanezumab (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy